MTOR and Kaposi's sarcoma: In contrast, mammalian target of rapamycin inhibitors are able to interfere with cancer cell proliferation and new angiogenesis process, and their use has been associated with a lower incidence of malignancies such as KS or mantle cell lymphoma [35].